The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 36 results
Sort by date: Descending
Encores: Not included
European Sleep Research Society
September 24th – 27th 2024
Sleep-wake disorders
POSTER
Vibrance-1: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 1
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Anne Marie Morse,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Vibrance-2: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 2
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Chad Ruoff,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Sleep-wake disorders
American Diabetes Association
June 21st – 24th 2024
Alcohol Use Disorder
POSTER
Comorbid Alcohol Use Disorder Is Associated With Increased Acute Care Utilization In Patients With Diabetes and Chronic Kidney Disease
AUTHOR(S)

Regina Grebla1, Lauren Strand1, Summera Zhou2, Xin Zhao2, Allison Keshishian3, Monica McClain2, Sandra Springer4

View poster
Alcohol Use Disorder
American Academy of Sleep Medicine
June 1st – 5th 2024
Sleep-wake disorders
POSTER
Vibrance-1: Study Design and Methods for a Phase 2, Randomized, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 1
AUTHOR(S)

David T. Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Anne Marie Morse,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Safety and Pharmacodynamic Effects of the Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 1: A First-in-Human Phase 1 Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Angela D’Rozario,1 Craig Hopkinson,2 Jandira Ramos,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
The Burden of Living With Narcolepsy: Patient Perspectives From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

View poster
Sleep-wake disorders